Literature DB >> 7884919

Retroviral vector particles displaying the antigen-binding site of an antibody enable cell-type-specific gene transfer.

T H Chu1, R Dornburg.   

Abstract

Retroviral vectors are the most efficient tool for stably introducing genes into vertebrate cells. However, their use is limited by the host range of the retrovirus from which they are derived. To alter the host range, we recently constructed retrovirus vector particles, derived from spleen necrosis virus, that display a single-chain antigen-binding site of an antibody (scA) on the viral surface (T.-H. T. Chu, I. Martinez, W. Sheay, and R. Dornburg, Gene Ther. 1:292-299, 1994). Using a hapten (2,4-dinitrophenol) model system, we showed that such particles are competent for infection. In this study, we repeated our experiments using an scA directed against a cell surface protein expressed on various human carcinoma cell lines. We found that such scA-displaying particles can efficiently infect human cells that express the corresponding antigen. Particles with wild-type spleen necrosis virus envelope are minimally infectious on such cells. The addition of the original monoclonal antibody to the viral vector particle solution prior to infection inhibited infection. This competition assay showed that the infection is mediated by the antibody moiety and, therefore, is antibody specific. These data indicate that retroviral vectors with antibody-envelope fusion proteins may be a valuable tool for selectively introducing genes into any target cell.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7884919      PMCID: PMC188950     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  18 in total

1.  A restriction enzyme cleavage map of Tn5 and location of a region encoding neomycin resistance.

Authors:  R A Jorgensen; S J Rothstein; W S Reznikoff
Journal:  Mol Gen Genet       Date:  1979

2.  Single-chain antigen-binding proteins.

Authors:  R E Bird; K D Hardman; J W Jacobson; S Johnson; B M Kaufman; S M Lee; T Lee; S H Pope; G S Riordan; M Whitlow
Journal:  Science       Date:  1988-10-21       Impact factor: 47.728

3.  The matrix region is responsible for the differential ability of two retroviruses to function as helpers for vector propagation.

Authors:  C R Casella; A T Panganiban
Journal:  Virology       Date:  1993-02       Impact factor: 3.616

4.  Retroviral vectors displaying functional antibody fragments.

Authors:  S J Russell; R E Hawkins; G Winter
Journal:  Nucleic Acids Res       Date:  1993-03-11       Impact factor: 16.971

Review 5.  Human gene therapy.

Authors:  R A Morgan; W F Anderson
Journal:  Annu Rev Biochem       Date:  1993       Impact factor: 23.643

6.  Role of reticuloendotheliosis virus envelope glycoprotein in superinfection interference.

Authors:  E L Delwart; A T Panganiban
Journal:  J Virol       Date:  1989-01       Impact factor: 5.103

Review 7.  Gene therapy of the immune system.

Authors:  D Cournoyer; C T Caskey
Journal:  Annu Rev Immunol       Date:  1993       Impact factor: 28.527

8.  Cell targeting with retroviral vector particles containing antibody-envelope fusion proteins.

Authors:  T H Chu; I Martinez; W C Sheay; R Dornburg
Journal:  Gene Ther       Date:  1994-09       Impact factor: 5.250

9.  Downstream insertion of the adenovirus tripartite leader sequence enhances expression in universal eukaryotic vectors.

Authors:  W Sheay; S Nelson; I Martinez; T H Chu; S Bhatia; R Dornburg
Journal:  Biotechniques       Date:  1993-11       Impact factor: 1.993

10.  Spleen necrosis virus, an avian immunosuppressive retrovirus, shares a receptor with the type D simian retroviruses.

Authors:  V N Kewalramani; A T Panganiban; M Emerman
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

View more
  25 in total

1.  Retroviral vectors preloaded with a viral receptor-ligand bridge protein are targeted to specific cell types.

Authors:  A L Boerger; S Snitkovsky; J A Young
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-17       Impact factor: 11.205

2.  Efficiency of expression of transfected genes depends on the cell cycle.

Authors:  S Marenzi; R L Adams; G Zardo; L Lenti; A Reale; P Caiafa
Journal:  Mol Biol Rep       Date:  1999-12       Impact factor: 2.316

3.  Identification of the block in targeted retroviral-mediated gene transfer.

Authors:  Y Zhao; L Zhu; S Lee; L Li; E Chang; N W Soong; D Douer; W F Anderson
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

4.  A TVA-single-chain antibody fusion protein mediates specific targeting of a subgroup A avian leukosis virus vector to cells expressing a tumor-specific form of epidermal growth factor receptor.

Authors:  S Snitkovsky; T M Niederman; B S Carter; R C Mulligan; J A Young
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

5.  Avian reticuloendotheliosis virus strain A and spleen necrosis virus do not infect human cells.

Authors:  R Gautier; A Jiang; V Rousseau; R Dornburg; T Jaffredo
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

6.  Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism.

Authors:  V N Krasnykh; G V Mikheeva; J T Douglas; D T Curiel
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

Review 7.  Vectors for cancer gene therapy.

Authors:  J Zhang; S J Russell
Journal:  Cancer Metastasis Rev       Date:  1996-09       Impact factor: 9.264

Review 8.  Development of retroviral vectors as safe, targeted gene delivery systems.

Authors:  W H Günzburg; B Salmons
Journal:  J Mol Med (Berl)       Date:  1996-04       Impact factor: 4.599

9.  Transfer of single gene-containing long terminal repeats into the genome of mammalian cells by a retroviral vector carrying the cre gene and the loxP site.

Authors:  A Choulika; V Guyot; J F Nicolas
Journal:  J Virol       Date:  1996-03       Impact factor: 5.103

Review 10.  Library screening and receptor-directed targeting of gammaretroviral vectors.

Authors:  Peter M Mazari; Monica J Roth
Journal:  Future Microbiol       Date:  2013-01       Impact factor: 3.165

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.